פריוריקס טטרה

Nazione: Israele

Lingua: ebraico

Fonte: Ministry of Health

Principio attivo:

LIVE ATTENUATED MEASLES VIRUS; LIVE ATTENUATED MUMPS VIRUS; LIVE ATTENUATED RUBELLA VIRUS; LIVE ATTENUATED VARICELLA VIRUS

Commercializzato da:

GLAXO SMITH KLINE (ISRAEL) LTD

Codice ATC:

J07BD54

Forma farmaceutica:

אבקה וממס להכנת תמיסה להזרקה

Composizione:

LIVE ATTENUATED MEASLES VIRUS 10^ 3.0 CCID50; LIVE ATTENUATED MUMPS VIRUS 10^ 4.4 CCID50; LIVE ATTENUATED RUBELLA VIRUS 10^ 3.0 CCID50; LIVE ATTENUATED VARICELLA VIRUS 10^ 3.3 PFU

Via di somministrazione:

תת-עורי

Tipo di ricetta:

מרשם נדרש

Prodotto da:

GLAXO SMITH KLINE BIOLOGICALS S.A

Gruppo terapeutico:

MEASLES, COMBINATIONS WITH MUMPS, RUBELLA AND VARICELLA, LIVE ATTENUATED

Area terapeutica:

MEASLES, COMBINATIONS WITH MUMPS, RUBELLA AND VARICELLA, LIVE ATTENUATED

Indicazioni terapeutiche:

Priorix-Tetra is indicated for active immunisation against measles, mumps, rubella and varicella in children from the age of 12 months up and including 12 years of age.

Data dell'autorizzazione:

2023-07-31